Top

Published in:

01-04-2018

Impact of chemotherapy-induced neurotoxicities on adult cancer survivors’ symptom burden and quality of life

Authors: Christine Miaskowski, Judy Mastick, Steven M. Paul, Gary Abrams, Steven Cheung, Jennifer Henderson Sabes, Kord M. Kober, Mark Schumacher, Yvette P. Conley, Kimberly Topp, Betty Smoot, Grace Mausisa, Melissa Mazor, Margaret Wallhagen, Jon D. Levine

Published in: Journal of Cancer Survivorship | Issue 2/2018

Abstract

Purpose

Limited information is available on the impact of chemotherapy (CTX)-induced neurotoxicity on adult survivors’ symptom experience and quality of life (QOL). Purposes were to describe occurrence of hearing loss and tinnitus and evaluate for differences in phenotypic characteristics and measures of sensation, balance, perceived stress, symptom burden, and QOL between survivors who received neurotoxic CTX and did (i.e., neurotoxicity group) and did not (i.e., no neurotoxicity group) develop neurotoxicity. Neurotoxicity was defined as the presence of chemotherapy-induced neuropathy (CIN), hearing loss, and tinnitus. Survivors in the no neurotoxicity group had none of these conditions.

Methods

Survivors (n = 609) completed questionnaires that evaluated hearing loss, tinnitus, stress, symptoms, and QOL. Objective measures of sensation and balance were evaluated.

Results

Of the 609 survivors evaluated, 68.6% did and 31.4% did not have CIN. Of the survivors without CIN, 42.4% reported either hearing loss and/or tinnitus and 48.1% of the survivors with CIN reported some form of ototoxicity. Compared to the no neurotoxicity group (n = 110), survivors in the neurotoxicity group (n = 85) were older, were less likely to be employed, had a higher comorbidity burden, and a higher symptom burden, higher levels of perceived stress, and poorer QOL (all p < .05).

Conclusions

Findings suggest that CIN, hearing loss, and tinnitus are relatively common conditions in survivors who received neurotoxic CTX.

Implications for cancer survivors

Survivors need to be evaluated for these neurotoxicities and receive appropriate interventions. Referrals to audiologists and physical therapists are warranted to improve survivors’ hearing ability, functional status, and QOL.

Sogaard M, Thomsen RW, Bossen KS, Sorensen HT, Norgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5(Suppl 1):3–29. https://doi.org/10.2147/CLEP.S47150clep-5-003.CrossRefPubMedPubMedCentral

Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, et al. Survivorship: screening for cancer and treatment effects, version 2.2014. J Natl Compr Cancer Netw. 2014;12(11):1526–31.CrossRef

Bellman SC. Monitoring chemotherapy-induced hearing loss in children. Eur J Cancer. 1996;32A(7):1185–8.CrossRefPubMed

Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012;30(19):2408–17. https://doi.org/10.1200/JCO.2011.39.1110.CrossRefPubMedPubMedCentral

Freyer DR, Sung L, Reaman GH. Prevention of hearing loss in children receiving cisplatin chemotherapy. J Clin Oncol. 2009;27(2):317–8. https://doi.org/10.1200/JCO.2008.20.1160.CrossRefPubMed

Landier W. Ototoxicity and cancer therapy. Cancer. 2016;122(11):1647–8. https://doi.org/10.1002/cncr.29779.CrossRefPubMed

Biro K, Noszek L, Prekopp P, Nagyivanyi K, Geczi L, Gaudi I, et al. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology. 2006;70(3):177–84.CrossRefPubMed

Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77(8):1355–62. https://doi.org/10.1038/bjc.1998.226.CrossRefPubMedPubMedCentral

Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol. 2007;25(6):708–14.CrossRefPubMed

10.

Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol. 2016;34(23):2712–20. https://doi.org/10.1200/JCO.2016.66.8822.CrossRefPubMedPubMedCentral

11.

Cheraghi S, Nikoofar P, Fadavi P, Bakhshandeh M, Khoie S, Gharehbagh EJ, et al. Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy. Med Oncol. 2015;32(7):646. https://doi.org/10.1007/s12032-015-0646-3.CrossRef

12.

Madasu R, Ruckenstein MJ, Leake F, Steere E, Robbins KT. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 1997;123(9):978–81. https://doi.org/10.1001/archotol.1997.01900090094014.CrossRefPubMed

13.

Salvinelli F, Casale M, Vincenzi B, Santini D, Di Peco V, Firrisi L, et al. Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect. J Exp Clin Cancer Res. 2003;22(1):155–8.PubMed

14.

Sarafraz M, Ahmadi K. Paraclinical evaluation of side-effects of Taxanes on auditory system. Acta Otorhinolaryngol Ital. 2008;28(5):239–42.PubMedPubMedCentral

15.

Ozguroglu M, Sari O, Turna H. Devastating effects of chemotherapy: deafness and acute renal failure in a patient with epithelial ovarian cancer. Int J Gynecol Cancer. 2006;16(Suppl 1):394–6. https://doi.org/10.1111/j.1525-1438.2006.00214.x.CrossRefPubMed

16.

Bacon M, James K, Zee B. A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC). Int J Gynecol Cancer. 2003;13(4):428–34. https://doi.org/10.1046/j.1525-1438.2003.13320.x.CrossRefPubMed

17.

Jenkins V, Low R, Mitra S. Hearing sensitivity in women following chemotherapy treatment for breast cancer: results from a pilot study. Breast. 2009;18(5):279–83. https://doi.org/10.1016/j.breast.2009.07.004.CrossRefPubMed

18.

Skalleberg J, Solheim O, Fossa SD, Smastuen MC, Osnes T, Gundersen PO, et al. Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer. Gynecol Oncol. 2017;145(1):148–53. https://doi.org/10.1016/j.ygyno.2017.02.006.CrossRefPubMed

19.

Baguley D, McFerran D, Hall D. Tinnitus. Lancet. 2013;382(9904):1600–7. https://doi.org/10.1016/S0140-6736(13)60142-7.CrossRefPubMed

20.

Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst. 2014;106(5):dju044. https://doi.org/10.1093/jnci/dju044.CrossRefPubMedPubMedCentral

21.

Johnson AC, Greenwood-Van MB. Stress-induced pain: a target for the development of novel therapeutics. J Pharmacol Exp Ther. 2014;351(2):327–35. https://doi.org/10.1124/jpet.114.218065.CrossRefPubMedPubMedCentral

22.

Betz LT, Muhlberger A, Langguth B, Schecklmann M. Stress reactivity in chronic tinnitus. Sci Rep. 2017;7:41521. https://doi.org/10.1038/srep41521.CrossRefPubMedPubMedCentral

23.

Heinecke K, Weise C, Schwarz K, Rief W. Physiological and psychological stress reactivity in chronic tinnitus. J Behav Med. 2008;31(3):179–88. https://doi.org/10.1007/s10865-007-9145-0.CrossRefPubMed

24.

Woda A, Picard P, Dutheil F. Dysfunctional stress responses in chronic pain. Psychoneuroendocrinology. 2016;71:127–35. https://doi.org/10.1016/j.psyneuen.2016.05.017.CrossRefPubMed

25.

Thieme K, Turk DC, Gracely RH, Maixner W, Flor H. The relationship among psychological and psychophysiological characteristics of fibromyalgia patients. J Pain. 2015;16(2):186–96. https://doi.org/10.1016/j.jpain.2014.11.009.CrossRefPubMed

26.

Ylikoski J, Lehtimaki J, Pirvola U, Makitie A, Aarnisalo A, Hyvarinen P, et al. Non-invasive vagus nerve stimulation reduces sympathetic preponderance in patients with tinnitus. Acta Otolaryngol. 2017;137(4):1–9. https://doi.org/10.1080/00016489.2016.1269197.CrossRef

27.

Vanneste S, De Ridder D. Brain areas controlling heart rate variability in tinnitus and tinnitus-related distress. PLoS One. 2013;8(3):e59728. https://doi.org/10.1371/journal.pone.0059728.CrossRefPubMedPubMedCentral

28.

Miaskowski C, Mastick J, Paul SM, Topp K, Smoot B, Abrams G, et al. Chemotherapy-induced neuropathy in cancer survivors. J Pain Symptom Manag. 2017;54(2):204–218.e2. https://doi.org/10.1016/j.jpainsymman.2016.12.342.CrossRef

29.

Victor TW, Jensen MP, Gammaitoni AR, Gould EM, White RE, Galer BS. The dimensions of pain quality: factor analysis of the pain quality assessment scale. Clin J Pain. 2008;24(6):550–5. https://doi.org/10.1097/AJP.0b013e31816b1058.CrossRefPubMed

30.

Karnofsky D. Performance scale. Factors that influence the therapeutic response in cancer: a comprehensive treatise. New York: Plenum Press; 1977.

31.

Karnofsky D, Abelmann WH, Craver LV, Burchenal JH. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer. 1948;1(4):634–56. https://doi.org/10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L.CrossRef

32.

Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, et al. Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. Cancer. 2008;113(8):2205–14. https://doi.org/10.1002/cncr.23856.CrossRefPubMedPubMedCentral

33.

Brunner F, Bachmann LM, Weber U, Kessels AG, Perez RS, Marinus J, et al. Complex regional pain syndrome 1—the Swiss cohort study. BMC Musculoskelet Disord. 2008;9(1):92. https://doi.org/10.1186/1471-2474-9-92.CrossRefPubMedPubMedCentral

34.

Cieza A, Geyh S, Chatterji S, Kostanjsek N, Ustun BT, Stucki G. Identification of candidate categories of the International Classification of Functioning Disability and Health (ICF) for a Generic ICF Core Set based on regression modelling. BMC Med Res Methodol. 2006;6(1):36. https://doi.org/10.1186/1471–2288–6-36.CrossRefPubMedPubMedCentral

35.

Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer. 2007;17(2):387–93.CrossRefPubMed

36.

Bell-Krotoski JA. Sensibility testing with Semmes-Weinstein monofilaments. In: Hunter JM, Mackin EJ, Callahan ED, editors. Rehabilitation of the hand and upper extremity. 5th ed. St. Louis: Mosby, Inc.; 2002.

37.

Viswanathan V, Snehalatha C, Seena R, Ramachandran A. Early recognition of diabetic neuropathy: evaluation of a simple outpatient procedure using thermal perception. Postgrad Med J. 2002;78(923):541–2. https://doi.org/10.1136/pmj.78.923.541.CrossRefPubMedPubMedCentral

38.

Papanas N, Ziegler D. New diagnostic tests for diabetic distal symmetric polyneuropathy. J Diabetes Complicat. 2011;25(1):44–51. https://doi.org/10.1016/j.jdiacomp.2009.09.006.CrossRefPubMed

39.

Duke J, McEvoy M, Sibbritt D, Guest M, Smith W, Attia J. Vibrotactile threshold measurement for detecting peripheral neuropathy: defining variability and a normal range for clinical and research use. Diabetologia. 2007;50(11):2305–12. https://doi.org/10.1007/s00125-007-0813-y.CrossRefPubMed

40.

Tofthagen CS, McMillan SC, Kip KE. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nurs. 2011;34(4):E10–20. https://doi.org/10.1097/NCC.0b013e31820251de.CrossRefPubMed

41.

Mathias S, Nayak US, Isaacs B. Balance in elderly patients: the “get-up and go” test. Arch Phys Med Rehabil. 1986;67(6):387–9.PubMed

42.

Hernandez D, Rose DJ. Predicting which older adults will or will not fall using the Fullerton Advanced Balance scale. Arch Phys Med Rehabil. 2008;89(12):2309–15. https://doi.org/10.1016/j.apmr.2008.05.020.CrossRefPubMed

43.

Rose DJ, Lucchese N, Wiersma LD. Development of a multidimensional balance scale for use with functionally independent older adults. Arch Phys Med Rehabil. 2006;87(11):1478–85. https://doi.org/10.1016/j.apmr.2006.07.263.CrossRefPubMed

44.

Spielberger CG, Gorsuch RL, Suchene R, Vagg PR, Jacobs GA. Manual for the state-anxiety (form Y): self evaluation questionnaire. Palo Alto: Consulting Psychologists Press; 1983.

45.

Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401. https://doi.org/10.1177/014662167700100306.CrossRef

46.

Lee KA, Hicks G, Nino-Murcia G. Validity and reliability of a scale to assess fatigue. Psychiatry Res. 1991;36(3):291–8. https://doi.org/10.1016/0165-1781(91)90027-M.CrossRefPubMed

47.

Lee KA. Self-reported sleep disturbances in employed women. Sleep. 1992;15(6):493–8. https://doi.org/10.1093/sleep/15.6.493.CrossRefPubMed

48.

Cimprich B, Visovatti M, Ronis DL. The attentional function index—a self-report cognitive measure. Psychooncology. 2011;20(2):194–202. https://doi.org/10.1002/pon.1729.CrossRefPubMed

49.

Fletcher BS, Paul SM, Dodd MJ, Schumacher K, West C, Cooper B, et al. Prevalence, severity, and impact of symptoms on female family caregivers of patients at the initiation of radiation therapy for prostate cancer. J Clin Oncol. 2008;26(4):599–605. https://doi.org/10.1200/JCO.2007.12.2838.CrossRefPubMed

50.

Miaskowski C, Lee KA. Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study. J Pain Symptom Manag. 1999;17(5):320–32. https://doi.org/10.1016/S0885-3924(99)00008-1.CrossRef

51.

Cimprich B, So H, Ronis DL, Trask C. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology. 2005;14(1):70–8. https://doi.org/10.1002/pon.821.CrossRefPubMed

52.

Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24(4):385–96. https://doi.org/10.2307/2136404.CrossRefPubMed

53.

Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. Psychosom Med. 1979;41(3):209–18. https://doi.org/10.1097/00006842-197905000-00004.CrossRefPubMed

54.

Weiss DS, Marmar CR. The Impact of Event Scale-Revised. Impact of Event Scale-Revised. New York: Guilford Press; 1997.

55.

Cuevas BT, Hughes DC, Parma DL, Trevino-Whitaker RA, Ghosh S, Li R, et al. Motivation, exercise, and stress in breast cancer survivors. Support Care Cancer. 2014;22(4):911–7. https://doi.org/10.1007/s00520-013-2038-6.CrossRefPubMed

56.

Creamer M, Bell R, Failla S. Psychometric properties of the Impact of Event Scale-Revised. Behav Res Ther. 2003;41(12):1489–96. https://doi.org/10.1016/j.brat.2003.07.010.CrossRefPubMed

57.

Civilotti C, Castelli L, Binaschi L, Cussino M, Tesio V, Di Fini G, et al. Dissociative symptomatology in cancer patients. Front Psychol. 2015;6:118. https://doi.org/10.3389/fpsyg.2015.00118.CrossRefPubMedPubMedCentral

58.

Sundin EC, Horowitz MJ. Impact of Event Scale: psychometric properties. Br J Psychiatry. 2002;180(3):205–9. https://doi.org/10.1192/bjp.180.3.205.CrossRefPubMed

59.

Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33. https://doi.org/10.1097/00005650-199603000-00003.CrossRefPubMed

60.

Padilla GV, Ferrell B, Grant MM, Rhiner M. Defining the content domain of quality of life for cancer patients with pain. Cancer Nurs. 1990;13(2):108–15.CrossRefPubMed

61.

Padilla GV, Presant C, Grant MM, Metter G, Lipsett J, Heide F. Quality of life index for patients with cancer. Res Nurs Health. 1983;6(3):117–26. https://doi.org/10.1002/nur.4770060305.CrossRefPubMed

62.

Ferrell BR, Dow KH, Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res. 1995;4(6):523–31. https://doi.org/10.1007/BF00634747.CrossRefPubMed

63.

Ferrell BR. The impact of pain on quality of life. A decade of research. Nurs Clin N Am. 1995;30(4):609–24.

64.

SPSS. IBM SPSS for windows (version 23). Armonk: SPSS, Inc.; 2015.

65.

Bainbridge KE, Wallhagen MI. Hearing loss in an aging American population: extent, impact, and management. Annu Rev Public Health. 2014;35(1):139–52. https://doi.org/10.1146/annurev-publhealth-032013-182510.CrossRefPubMed

66.

Hsu WT, Hsu CC, Wen MH, Lin HC, Tsai HT, Su P, et al. Increased risk of depression in patients with acquired sensory hearing loss: a 12-year follow-up study. Medicine. 2016;95(44):e5312. https://doi.org/10.1097/md.0000000000005312.CrossRefPubMedPubMedCentral

67.

Holgers KM, Erlandsson SI, Barrenas ML. Predictive factors for the severity of tinnitus. Audiology. 2000;39(5):284–91. https://doi.org/10.3109/00206090009073093.CrossRefPubMed

68.

Pattyn T, Van Den Eede F, Vanneste S, Cassiers L, Veltman DJ, Van De Heyning P, et al. Tinnitus and anxiety disorders: a review. Hear Res. 2016;333:255–65. https://doi.org/10.1016/j.heares.2015.08.014.CrossRefPubMed

69.

Tseng CC, Hu LY, Liu ME, Yang AC, Shen CC, Tsai SJ. Risk of depressive disorders following sudden sensorineural hearing loss: a nationwide population-based retrospective cohort study. J Affect Disord. 2016;197:94–9. https://doi.org/10.1016/j.jad.2016.03.020.CrossRefPubMed

70.

Gewandter JS, Fan L, Magnuson A, Mustian K, Peppone L, Heckler C, et al. Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer. 2013;21(7):2059–66. https://doi.org/10.1007/s00520-013-1766-y.CrossRefPubMedPubMedCentral

71.

Xiao C, Miller AH, Felger J, Mister D, Liu T, Torres MA. Depressive symptoms and inflammation are independent risk factors of fatigue in breast cancer survivors. Psychol Med. 2017;47(10):1–11. https://doi.org/10.1017/s0033291717000150.CrossRef

72.

Penedo FJ, Benedict C, Zhou ES, Rasheed M, Traeger L, Kava BR, et al. Association of stress management skills and perceived stress with physical and emotional well-being among advanced prostrate cancer survivors following androgen deprivation treatment. J Clin Psychol Med Settings. 2013;20(1):25–32. https://doi.org/10.1007/s10880-012-9308-1.CrossRefPubMed

73.

Mayer DK, Nasso SF, Earp JA. Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA. Lancet Oncol. 2017;18(1):e11–e8. https://doi.org/10.1016/s1470-2045(16)30573-3.CrossRefPubMed

74.

Mols F, Vingerhoets AJ, Coebergh JW, van de Poll-Franse LV. Quality of life among long-term breast cancer survivors: a systematic review. Eur J Cancer. 2005;41(17):2613–9. https://doi.org/10.1016/j.ejca.2005.05.017.CrossRefPubMed

75.

Jacobs LA, Shulman LN. Follow-up care of cancer survivors: challenges and solutions. Lancet Oncol. 2017;18(1):e19–29. https://doi.org/10.1016/s1470-2045(16)30386-2.CrossRefPubMed

76.

Sloan JA, Frost MH, Berzon R, Dueck A, Guyatt G, Moinpour C, et al. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer. 2006;14(10):988–98. https://doi.org/10.1007/s00520-006-0085-y.CrossRefPubMed

77.

Osoba D. Interpreting the meaningfulness of changes in health-related quality of life scores: lessons from studies in adults. Int J Cancer Suppl. 1999;12(S12):132–7. https://doi.org/10.1002/(SICI)1097-0215(1999)83:12+<132::AID-IJC23>3.0.CO;2-4.CrossRefPubMed

Title: Impact of chemotherapy-induced neurotoxicities on adult cancer survivors’ symptom burden and quality of life
Authors: Christine Miaskowski
Judy Mastick
Steven M. Paul
Gary Abrams
Steven Cheung
Jennifer Henderson Sabes
Kord M. Kober
Mark Schumacher
Yvette P. Conley
Kimberly Topp
Betty Smoot
Grace Mausisa
Melissa Mazor
Margaret Wallhagen
Jon D. Levine
Publication date: 01-04-2018
Publisher: Springer US
Published in: Journal of Cancer Survivorship / Issue 2/2018
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-017-0662-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Implications for cancer survivors

Please log in to get access to this content

Other articles of this Issue 2/2018

Modifiable correlates of perceived cognitive function in breast cancer survivors up to 10 years after chemotherapy completion

Coping and adjustment in men with prostate cancer: a systematic review of qualitative studies

Bright light therapy improves cancer-related fatigue in cancer survivors: a randomized controlled trial

Relationship between self-reported cognitive function and work-related outcomes in breast cancer survivors

Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy

Predictors for earlier return to work of cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer